by Tyler Hale The U.S. Food and Drug Administration has approved a new drug that has the potential to treat the most common form of cystic fibrosis mutation, the F508del mutation. On Tuesday, Oct. 21, the FDA approved Trikafta, a…
by Tyler Hale The U.S. Food and Drug Administration has approved a new drug that has the potential to treat the most common form of cystic fibrosis mutation, the F508del mutation. On Tuesday, Oct. 21, the FDA approved Trikafta, a…